A recent review confirms the safety and efficacy of biosimilar insulins, addressing concerns and promoting their adoption for ...

Number 5: Pediatric infliximab biosimilar use has risen significantly, reflecting evolving treatment patterns in inflammatory bowel disease (IBD) among children and young adults. Number 4: About 13% ...

Biosimilar SB12 or Epysqli (eculizumab-aagh; Samsung Bioepis) is equivalent to reference eculizumab (Soliris) for treating complement inhibitor-naïve patients with paroxysmal nocturnal hemoglobinuria ...

Number 5: Leading biosimilar companies Sandoz, STADA Arzneimittel, and Samsung Bioepis report impressive Q1 2025 growth, driven by strong denosumab biosimilars and expanding portfolios. Number 4: ...

The narrative literature review, published in Diabetes, Obesity and Metabolism, was conducted to address persistent challenges in realizing the full benefits of insulin therapy and to emphasize the ...